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Interferon regulatory factor-1 is a transcription factor
that is linked to the expression of genes important in
the initiation of the in£ammatory response and the con-
trol of cell cycle. In this study, we determined that the
generation of interferon regulatory factor-1 expression
in human dermal microvascular endothelial cells was
transcriptionally mediated by tumor necrosis factor-a
or interferon-c via iron-dependent pathways. The induc-
tion of interferon regulatory factor-1 protein and the up-
regulation of interferon regulatory factor-1 mRNA
levels was inhibited when cells were pretreated with the
iron chelators 2-2-dipyridyl or deferoxamine.This inhi-
bition of interferon regulatory factor-1 expression was
associated with loss of interferon regulatory factor-1
binding to the interferon-stimulated response element
as assessed by electrophoretic mobility shift assay. Addi-
tion of exogenous iron with the iron chelator resulted in
reconstitution of cytokine responsiveness, thus demon-
strating iron as the target for the chelator e¡ect. Both
tumor necrosis factor-a and interferon-c-induced inter-
feron regulatory factor-1 gene transcription, as assessed
by the measurement of unspliced, nascent, heteroge-
neous nuclear RNA, and treatment with iron chelators
blocked tumor necrosis factor-a or interferon-c media-
ted interferon regulatory factor-1 gene transcription.
Iron was not essential, however, for the association of
interferon regulatory factor-1 mRNA with polyribo-
somes, suggesting iron was not essential for interferon
regulatory factor-1 protein translation. Through such
inhibitory regulation on pro-in£ammatory transcrip-
tion factors, iron chelators may serve as anti-in£amma-
tory agents. Key words: transcription factor/cytokine. J Invest
Dermatol 121:1191 ^1196, 2003
I
nterferon regulatory factor (IRF)-1, which was initially
identi¢ed as a regulator of interferon (IFN)-b gene expres-
sion, belongs to a nine-member family of transcription fac-
tors characterized by a highly conserved amino-terminal
DNA binding domain (Sato et al, 2001; Taniguchi et al,
2001). IRF-1 acts as a transcriptional activator and has been linked
to the expression of a number of pro-in£ammatory cytokines
and cell cycle regulatory genes (Miyamoto et al, 1988; Sanceau
et al, 1995; Lechleitner et al, 1998; Sato et al, 2001). Speci¢cally,
IRF-1 induces gene expression by binding to interferon-stimu-
lated response elements (ISRE) and regulates the transcription
of pro-in£ammatory genes, including vascular cell adhesion mo-
lecule (VCAM)-1, inducible nitric oxide synthase (iNOS), inter-
leukin-12, interleukin-15, cyclooxygenase II, angiotensin II type 2
receptor, and interleukin 1b converting enzyme (Neish et al, 1995;
Sanceau et al, 1995). IRF-1 is involved in the di¡erentiation of
CD8þ T cells, T helper 1 subsets of CD4þ T cells, and natural
killer cells (Mamane et al, 1999). It has also been implicated as a
tumor suppressor gene due to its role in promoting apoptosis,
and loss of IRF-1, which has been mapped to 5q31.1, has been
linked to the development of human hematopoietic malignancies
(Miyamoto et al, 1988; Harada et al, 1989; Tanaka and Taniguchi,
2000).
In human umbilical vein endothelial cells, low levels of IRF-1
protein may be present in unstimulated cells, but markedly in-
creased expression results within 4 h after treatment with either
tumor necrosis factor (TNF)-a or IFN-g (Lechleitner et al, 1998;
Ochi et al, 2002). IRF-1 has also been shown to be induced by
viral infection, leukocyte inhibitory factor, and lipopolysacchar-
ide (Sims et al, 1993; Harada et al, 1994). Evidence exists for the
presence of both TNF-a-induced nuclear factor (NF)-kB activa-
tion and IFN-g-induced Jak/STAT signaling pathways in the reg-
ulation of IRF-1 expression. Limited studies have been done in
endothelial cells, particularly microvascular endothelium and
cell-speci¢c di¡erences in cytokine-induced IRF-1 expression
may exist (Lechleitner et al, 1998; Liu et al, 2001).
Iron, which is present intracellularly in its ferrous form (Fe2þ ),
is a necessary element for cell growth and proliferation (Conrad,
1998); however, excess ferrous iron is capable of acting as a catalyst
in the Fenton reaction to generate reactive oxygen species and
to increase lipid peroxidation, both of which can induce tissue
damage and promote tissue in£ammation (McCord, 1998).
In£ammatory skin diseases in which excess iron has been found
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include psoriasis (Molin and Wester, 1973), venous ulceration
(Ackerman et al, 1988), atopic dermatitis (David et al, 1990), and
ultraviolet-irradiated skin (Bissett et al, 1991, 1994).
There is a growing list of iron-regulated genes, including
iNOS, protein kinase C-b, acid phosphatase type 5 (Acp5)/tar-
trate resistant acid phosphatase, hypoxia inducible factor 1a, and
p21WAF1/CIP1 (Boldt, 1999; Alcantara et al, 2001). The mechanisms
through which iron regulates gene transcription are multiple.We
have previously investigated the role of iron in TNF-a-induced
VCAM-1 gene expression in human dermal microvascular en-
dothelial cells (HDMEC) (Koo et al, 2003), and found TNF-a
mediated induction of VCAM-1 to be iron dependent. Further-
more, we observed that a portion of this iron dependence is
mediated via iron-dependent induction of IRF-1.
In this study, we examined the role of iron in the regulation of
IRF-1 expression in HDMEC.We observed that bothTNF-a and
IFN-g induction of IRF-1 required iron for transcriptional acti-
vation of the IRF-1 gene and that loss of IRF-1 expression was
accompanied by loss of IRF-1 binding to the ISRE on a target
promoter.
MATERIALS AND METHODS
Cell culture Cultures of HDMEC immortalized with SV40 large T
(5A32 cells) were utilized and passaged as described previously (Ades et al,
1992). Cells were grown in £asks coated with 0.1% gelatin in MCDB 131
media (Mediatech, Herndon, Virginia) supplemented with 10% (v/v) fetal
bovine serum (Hyclone, Logan, Utah), 1% penicillin/streptomycin
(Mediatech), 2 mM L-glutamine (Mediatech), 0.25 mg cyclic adenosine
monophosphate per mL, and 1 mg hydrocortisone per mL (Sigma, St
Louis, Missouri) and maintained at 371C in a humidi¢ed atmosphere of
5% CO2.
Reagents and antibodies The speci¢c iron chelators 2-2-dipyridyl
(DP) and deferoxamine (DFO) (Syvertsen and McKinley-McKee, 1984;
Horky et al, 1998; Liu and Hider, 2002), which, respectively, bind ferrous
iron (Fe2þ ) and ferric iron (Fe3þ), were obtained from Sigma. Recom-
binant human TNF-a and IFN-g were purchased from R&D Systems,
Inc. (Minneapolis, Minnesota). Anti-IRF-1 antibody was obtained from
Santa Cruz Biotechnology Inc. (Santa Cruz, California).
Measurement of IRF-1 mRNA and heterogeneous nuclear IRF-1
RNA (hnRNA) expression 5A32 cells were either pretreated with DP
or DFO for 24 h followed by treatment with IFN-g or TNF-a. mRNA
expression of IRF-1 was measured by real-time quantitative polymerase
chain reaction (PCR). Brie£y, total RNA was isolated with TriReagent
(Sigma) from 5A32 HDMEC according to the manufacturer’s instruc-
tions. cDNA was prepared using the Superscript Preampli¢cation System
for 1st Strand cDNA Synthesis (Gibco, Carlsbad, California) using the
random primer protocol. Real-time PCR was done using SYBR green
technology with Perkin-Elmer 5700 Gene-Amp Detection System with
IRF-1 primers (forward sequence CTT TCG CTG TGC CAT GAA CTC
and reverse sequence AGC TGC CCT TGT TCC TGC T). Data were
normalized with primers for GAPDH housekeeping gene. Relative
quantities were determined by generating a standard curve from dilutions
of cDNA containing the message of interest. Data were then expressed as
fold increase over control.
IRF-1 hnRNA expression was measured to assess the e¡ect of iron
chelation on the transcription of the IRF-1 gene using a modi¢cation of
the above technique (Elferink and Reiners, 1996). Prior to reverse
transcription, total RNAwas treated with RNAse-free DNAse for 1 h at
room temperature to destroy any potential contaminating genomic DNA.
DNAse was inactivated by heating at 751C for 30 min. IRF-1 primers were
selected from an intron segment that would amplify only nascent,
unspliced hnRNA (forward sequence AAT TTT GTT GGA TAT GTT
TTC TCA TTT C located at intron 2 and reverse sequence CTG GCA
TTG TCA CTG TAT CTC TTT G located at intron 2). All primers were
synthesized by Emory University Microchemical Facility.
Western blot Cells were washed with phosphate-bu¡ered saline twice
and whole cell extracts were prepared by lysis with 50 mM, pH 8.0 Tris,
150 mM NaCl, 0.02% Na azide, 1 mg aprotinin per mL, 1% Triton X,
1 mM phenylmethylsulfonyl £uoride. The suspension was centrifuged at
13,000 g for 15 min at 41C, and the protein in the supernatant was
quanti¢ed using the Bio-Rad DC Protein Assay (Bio-Rad Laboratories,
Hercules, CA).Whole cell protein extract was resolved on a 10% sodium
dodecyl sulfate^polyacrylamide gel electrophoresis using reducing
concentrations. After transfer to hybond enhanced chemiluminescence
nitrocellulose (Amersham Pharmacia Biotech, Piscataway, NJ), the gel was
stained with Ponceau S (Sigma) to verify uniform loading and transfer.
Membranes were blocked with 5% bovine serum albumin in TBS-T (50
mmol per liter Tris^HCl, 150 mmol per liter NaCl, 0.1% Tween 20, pH
7.4) overnight and subsequently incubated with primary antibodies (rabbit
polyclonal IRF-1 antibody 1:500) for 1 h at room temperature. The
membrane was washed with TBS-T three times and incubated for 1 h
at room temperature with the appropriate goat antirabbit horseradish
peroxidase-conjugated secondary antibody. Subsequently, the membrane
was washed three times with TBS-T and analyzed by enhanced chemi-
luminescence (ECL Reagent, Amersham Pharmacia Biotech).
Electrophoretic mobility shift assay Nuclear extracts were pre-
pared as described previously (Naik et al, 1997). All oligonucleotides
were synthesized at the Emory University Microchemical Facility.
Oligonucleotides used included the following: ISRE-like site of the
iNOS promoter (forward sequence 50 -TGA AAA AAA GGG AAA CGA
AGA C-30 and reverse sequence 50 -G TCT TCG TTT CCC TTT TTT
TCA-30) and the NF-kB-like site of the VCAM-1 promoter (forward
sequence 50 -CTG CCC TGG GTT TCC CCT TGA AGG GAT TTC
CCT CCG CCT-30 and reverse sequence 50 -AGG CGG AGG GAA ATC
CCT TCA AGG GGA AAC CCA GGG CAG-30). All double-stranded
oligonucleotides formed by annealing reaction were completed by ¢ll-
in reaction using Klenow. The [a-32P]deoxycytidine triphosphate-
labeled probe was 50 end labeled using the forward reaction with T4
polynucleotide kinase. The DNA binding reaction was performed under
previously described conditions (Naik et al, 1997). The speci¢city of the
IRF-1/iNOS and NF-kB/VCAM-1 binding complexes were de¢ned by
utilizing cold competition and by supershift analysis with anti-IRF-1 and
anti-p65 antibodies, respectively. Cold competitor and antibodies were
added 30 min before adding the [a-32P]deoxycytidine triphosphate-
labeled probe to the binding reaction. Samples were separated on 4%
native polyacrylamide gel for 4 h at 130 V. Gels were dried and
autoradiography was performed.
Polyribosomal analysis Co-localization of IRF-1 mRNA with
polyribosomes was analyzed via a sucrose gradient. 5A32 cells were either
treated with DP and/or IFN-g. Prior to mRNA extraction, the above
treatment media was removed from plated cells and replaced with media
containing 150 mg cycloheximide per mL for 15 min. Total mRNA was
extracted from each condition. Brie£y, whole cell lysates were prepared
by scraping cells in 500 mL of ice-cold lysis bu¡er comprised of 10 mM
Tris^Cl (pH 7.2), 150 mM KCl, 10 mM MgCl2, 150 mg cycloheximide per
mL, 0.5 mg heparin per mL, 0.5% Triton X-100, 20 mM dithiothreitol (all
from Sigma), and 100 U RNAsin per mL (from PharMingen San Diego,
CA) using diethypyrocarbonate (Sigma) treated and autoclaved water.
Cells were left on ice for 10 min and then centrifuged for 10 min at
15,000 g. Supernatants were gently overlayed on to a linear 10 to 50%
(by weight) sucrose gradient, which was poured in 12 mL Beckman
polyallomer tubes (14 89 mm) containing sucrose (from Sigma) in
20 mMHEPES, 250 mMKCl,10 mMMgCl2, 20 mMdithiothreitol,150 mg
cycloheximide, 0.5 mg heparin per ml, 10 U RNAsin per mL.The gradients
were centrifuged at 192,072 g. for 1.25 h. Twelve 1.05 mL fractions were
extracted from each gradient. Real-time reverse transcription^PCR as
previously described was performed to quantify mRNA amounts found
in each fraction. Reverse transcription reactions were done using a set
amount of volume (10 mL) from each fraction. Percentages of mRNA
found in each fraction were calculated as ((quantity mRNA in fraction)/
(total quantity mRNA in all 12 fractions)) 100.
RESULTS
Previous studies examining VCAM-1 expression in HDMEC
identi¢ed that TNF-a-mediated induction of IRF-1 protein was
iron dependent (Koo et al, 2003). In order to characterize the me-
chanisms mediating this iron requirement and to determine
whether iron-dependent synthesis was speci¢c for TNF-a, we
determined if TNF-a and IFN-g induction of IRF-1 protein
and mRNA could be blocked by the pretreatment with iron
chelators. Both cytokines induced IRF-1 protein and mRNA
rapidly, with maximal levels observed after 2 h of cytokine
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stimulation (data not shown). Cultures of 5A32 endothelial cells
were pretreated with DP or DFO (250^1000 mmol) and then trea-
ted withTNF-a (500 U per mL) or IFN-g (1000 U per mL) for 2
h. DP or DFO pretreatment prior to IFN-g treatment resulted in
a concentration-dependent inhibition of IRF-1 mRNA induc-
tion (data not shown). Complete inhibition of the induction of
both IRF-1 protein and mRNA by either TNF-a or IFN-g re-
quired 24 h of DP pretreatment, and treatment with DP or
DFO for 4 or 8 h resulted in only partial inhibition of TNF-a
or IFN-g-induced IRF-1 expression (Fig 1A^D). Viability of
5A32 cells, as assessed by trypan blue or propidium iodide exclu-
sion, was not a¡ected by treatment of cells with either DP or
DFO at concentrations as high as 1 mM for 24 h (data not
shown).
To demonstrate that the chelator e¡ect was actually mediated
via the binding of iron, we examined whether the inhibition
could be reversed with the addition of exogenous iron. Exogen-
ous iron in the form of ferric citrate was combined with DFO
prior to preincubation with 5A32 cells. Addition of ferric citrate
to DFO in stoichiometric ratios from 0.5:1 to 2:1 blocked DFO-
mediated inhibition of IFN-g- or TNF-a-mediated induction of
IRF-1 protein and mRNA. Furthermore, at least a 1:1 ratio was
needed to reverse the inhibitory e¡ect of DFO (Fig 1E, F). These
data demonstrate that iron chelator e¡ects on IRF-1 expression
are speci¢cally mediated via e¡ects on iron concentration and
not via a nonspeci¢c iron-independent mechanism.
IRF-1 serves as a transcriptional activator of both pro-in£am-
matory and cell cycle regulatory genes, including iNOS (Boldt,
1999; Alcantara et al, 2001). Upon appropriate cytokine stimula-
tion, IRF-1 binds to ISRE located in the promoters of target
genes (Neish et al, 1995; Sanceau et al, 1995). In order to assess
whether decreased IRF-1 expression was accompanied by loss of
binding to ISRE in IRF-1 responsive genes, we utilized electro-
phoretic mobility shift assay. IFN-g treatment of 5A32 endothe-
lial cells resulted in IRF-1 binding as assessed by electrophoretic
mobility shift assay and supershift studies using iNOS promoter
based oligonucleotides. Consistent with whole cell mRNA and
protein data, pretreatment of 5A32 cells for 24 h with DP (500
mM) inhibited this IFN-g-mediated complex formation, demon-
strating that decreased IRF-1 protein expression is associated with
commensurate decreases in IRF-1 binding to the ISRE of the
iNOS promoter (Fig 2A).
This iron requirement of IFN-g- or TNF-a-induced IRF-1
expression was not due to a global e¡ect on multiple signaling
pathways. 5A32 endothelial cells were pretreated with DP (500
mM) for 24 h followed by treatment with TNF-a. In contrast to
e¡ects on IFN-g-mediated IRF-1 binding to the iNOS promoter,
pretreatment with DP did not inhibit p65 subunit binding to the
VCAM-1 promoter (Fig 2B), consistent with observations made
previously (Koo et al, 2003).
Changes in steady-state IRF-1 mRNA levels may be due to
iron-mediated changes in mRNA stability or due to changes in
overall IRF-1 gene transcription. In order to address whether
IFN-g and TNF-a induction of IRF-1 was mediated via a tran-
scriptional mechanism, we measured the expression of IRF-1
hnRNA using primers that recognized intronic sequences speci-
¢c for transiently expressed, unspliced hnRNA (Fig 3A). In-
creased expression of hnRNAwas detected in 5A32 endothelial
cells treated with IFN-g or TNF-a (500 U per mL) by real-time
reverse transcription^PCR. To ensure that detection of nascent
message was not the consequence of ampli¢cation of contaminat-
ing genomic DNA, samples were DNAsed prior to reverse tran-
scription reactions. PCR products were not detected in samples
treated with DNAase without subsequent reverse transcription
reaction, thus demonstrating that any product detected in the
experimental samples was due to authentic ampli¢cation of
Figure1. DP blocks IFN-c and TNF-a in-
duction of IRF-1 in HDMEC: Time course.
5A32 HDMEC were pretreated with DP (1000
mM) for 4, 8, or 24 h and then treated with IFN-
g (1000 U per mL) or TNF-a (500 U per mL)
for 2 h. IRF-1 protein expression as determined
by western blotting (A,C) and mRNA as deter-
mined by real-time quantitative reverse trans-
cription^PCR (B,D) were inhibited by DP
pretreatment with maximal inhibition requiring
24 h of pretreatment. DFO inhibition of IRF-1
induction is reversed by addition of exogenous
iron. 5A32 HDMEC were pretreated with DFO
(500 mM) combined with varying doses of Fe3þ
for 24 h and then treated with (E) TNF-a (500 U
per mL) or (F) IFN-g (500 U per mL) for 2 h. As
determined by western blotting, increasing Fe3þ
amounts reversed the DFO inhibition of TNF-a-
and IFN-g-induced IRF-1 protein.
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hnRNA by reverse transcription and not by ampli¢cation of
genomic DNA (data not shown).
Consistent with measurements of cytokine-induced IRF-1
protein and mRNA (data not shown), IFN-g induced a more
persistent expression of IRF-1 hnRNA than TNF-a (Fig 3B,
C). The induction of hnRNAwas completely inhibited by pre-
treatment with either actinomycin D (1 mg per mL 30 min) or
DP (500 mM for 24 h) (data not shown). These data suggest that
IFN-g and TNF-a induce increases in IRF-1 mRNA via a tran-
scriptional mechanism, and that IFN-g- and TNF-a-mediated
transcriptional induction of IRF-1 mRNA is iron dependent.
In the face of modest increases in steady-state IRF-1 mRNA
levels, we observed striking induction of IRF-1 protein expres-
sion. These observations suggested that, although our data pro-
vide evidence of iron-dependent transcriptional controls of the
IRF-1 gene, the increased expression of IRF-1 protein may be
controlled via additional nontranscriptional controls. Previous
work of ferritin and transferrin protein expression has demon-
strated the dominant target for iron is at the level of protein
translation, although modest transcriptional e¡ects of iron have
also been noted. It was possible that, like ferritin or transferrin,
IRF-1 expression may also be regulated by iron at the level of
translation (Klausner et al, 1993). The presence or absence of iron
regulates the ability of speci¢c mRNA species (such as ferritin) to
associate with polyribosomes.
In order to address whether iron-controlled IRF-1 protein
synthesis occurs via a similar post-transcriptional mechanism,
we utilized polyribosomal analysis via a sucrose gradient to
examine IRF-1 mRNA colocalization with polyribosomes. In
order to induce su⁄cient IRF-1 mRNA for polysome analysis,
5A32 cells were initially treated with either IFN-g (500 U per
mL) alone for 2 h or with IFN-g (500 U per mL) for 2 h fol-
lowed by DP (500 mM) treatment for 6 h.Treatment of 5A32 cells
with DP did not alter the pattern of association of IRF-1mRNA
with polysomes (data not shown). In order to assess whether DP
treatment resulted in su⁄cient alteration of intracellular iron to
a¡ect iron-dependent translational controls, we examined asso-
ciation of ferritin mRNA with polysomes, with and without
DP treatment. In contrast with IRF-1 mRNA, treatment of
5A32 with DP resulted in a shift of ferritin mRNA to fractions
Figure 2. (A) Inhibition of IRF-1 expression is associated with loss
of IRF-1 binding to the ISRE of the iNOS promoter. As assessed by
electrophoretic mobility shift assay and supershift studies using iNOS pro-
moter-based oligonucleotides, IFN-g treatment of 5A32 HDMEC resulted
in formation of complex A, which was supershifted with IRF-1 antibody
(band B). Pretreatment of 5A32 cells for 24 h with DP (500 mM) inhibited
IFN-g-mediated complex formation (complex A) and loss of supershifted
protein (band B), thus demonstrating that decreased IRF-1 protein expres-
sion is associated with decreased IRF-1 binding to the ISRE of the iNOS
promoter. (B) TNF-a-induced activation of the p65 subunit and subse-
quent binding to the VCAM-1 promoter does not require iron. 5A32
HDMEC were stimulated with TNF-a (500 U per mL) for 30 min with
or without DP (500 mM) pretreatment for 24 h. TNF-a treatment resulted
in the formation of complex A, which supershifts with anti-p65 antibody
(band B), and is not a¡ected by the pretreatment of cells with DP.
Figure 3. IFN-c- and TNF-a-mediated increases of IRF-1 mRNA
are transcriptionally regulated. Transcriptional regulation of IRF-1
hnRNA was analyzed by real-time quantitative reverse transcription^
PCR, using primers spanning intron segment 2. (A) Unspliced, nascent
hnRNA is the primary RNA formed after transcription. 5A32 HDMEC
were treated with IFN-g (1000 U per mL) for 0.5 to 16 h (B) orTNF-a (500
U per mL) for 0.5 to 24 h (C).
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less associated with polysomes (Fig 4). These data demonstrate
that in our cell model, treatment of HDMEC with iron chelators
sequesters the intracellular iron pool as evidenced by its e¡ects on
ferritin mRNA association with polysomes. Furthermore, these
data in concert with transcriptional studies provide evidence that
the major regulatory mechanism controlling IRF-1 expression by
IFN-g and TNF-a is transcriptional and not via a translational
mechanism.
DISCUSSION
IRF-1was originally identi¢ed through transcriptional studies of
the IFN-b gene (Harada et al, 1994; Mamane et al, 1999). Subse-
quent studies demonstrated IRF-1 expression in a number of cell
types after exposure to double-stranded RNA, a response that is
important as a response to viral infection (Sims et al, 1993; Har-
court et al, 2000). Promoters of genes responding to IRF-1 con-
tain ISRE, to which IRF-1 binds and controls gene expression
(Taniguchi et al, 2001).
Because of its dual roles as a regulator of pro-in£ammatory
mediators and cell cycle, IRF-1 is an important transcription fac-
tor in endothelial cells. IRF-1 controls the expression of major
histocompatibility complex class I and II proteins and the expres-
sion of pro-in£ammatory genes, such as VCAM-1 and interleu-
kin-6 (Neish et al, 1995; Sanceau et al, 1995; Hobart et al, 1997). It
has also been linked to the expression of cyclooxygenase II and
the angiotensin II type 2 receptor, implicating a role in vascular
in£ammation and injury. IRF-1 also plays an important part in
cell proliferation and survival and has been designated as a tumor
suppressor gene. Its importance in that role is underscored by the
observation that loss of IRF-1 is associated with the development
of human cancers, including pre-leukemic myelodysplastic syn-
drome, esophageal cancers, and gastric cancers (Lin and Hiscott,
1999; Tanaka and Taniguchi, 2000; Taniguchi et al, 2001).
Limited studies have been done examining IRF-1 expression
in endothelial cells, particularly microvascular endothelial cells
(Lechleitner et al, 1998; Harcourt et al, 2000; McMullen et al,
2000; Liu et al, 2001; Ochi et al, 2002; Wagner et al, 2002; Wu
et al, 2002). Increases in IRF-1 protein were accompanied by
commensurate increases in IRF-1 mRNA and hnRNA, with the
induction of hnRNA providing evidence that the upregulation
of IRF-1 in 5A32 cells by either TNF-a or IFN-g was mediated
via a transcriptional mechanism. IFN-g stimulation resulted in a
more prolonged response than TNF-a stimulated, with near
maximal levels of IRF-1 protein and active transcription persist-
ing after 16 h of stimulation.
Previous studies demonstrated that pretreatment of HDMEC
with iron chelators prior toTNF-a stimulation prevented expres-
sion of IRF-1 protein, thus providing evidence that IRF-1 induc-
tion byTNF-a in endothelial cells was iron dependent (Koo et al,
2003).We have extended these observations in this study to de-
monstrate that induction of IRF-1 protein by either TNF-a and
IFN-g requires the presence of iron. Furthermore, we have
further demonstrated that iron is essential for transcriptional acti-
vation of the IRF-1 gene induction by either TNF-a or IFN-g.
Multiple pieces of evidence support the iron requirement. First,
agents such as DP or DFO that bind iron inhibited induction of
IRF-1 protein expression and mRNA upregulation by either
TNF-a or IFN-g. That the inhibition was mediated speci¢cally
via iron chelation was further supported by reversal of the chela-
tor e¡ect and restoration of IRF-1 induction when iron was
added back. Furthermore, treatment of HDMEC with iron che-
lators clearly altered intracellular levels of iron as evidenced by
changes in ferritin association with polysomes (Klausner et al,
1993). That the e¡ect of iron chelators was mediated primarily
by inhibition of IRF-1 gene transcription and not by iron-regu-
lated translational controls was supported by our data showing
iron chelators inhibited cytokine-mediated increases in nascent
IRF-1 hnRNA without alteration of IRF-1 mRNA association
with polysomes.
Iron plays a crucial part in regulating the expression of genes
such as iNOS, protein kinase C-b, acid phosphatase type 5
(Acp5)/tartrate resistant acid phosphatase, hypoxia inducible fac-
tor 1a, and p21WAF1/CIP1 (Boldt, 1999; Alcantara et al, 2001). In
the case of hypoxia inducible factor 1a, iron is required for gene
suppression. This suppression is mediated via an iron dependent
proline hydroxylase, which controls hypoxia inducible factor 1a
interaction with VHL protein (Ivan et al, 2001). In contrast, the
mechanisms by which iron regulates the expression of protein ki-
nase C-b, Acp5 (type 5 isoenzyme of acid phosphatase/tartrate
resistant acid phosphatase), and the cyclin-dependent kinase
inhibitor, p21WAF1/CIP1 (Boldt, 1999) are not well characterized.
The mechanisms mediating the iron dependence of IFN-g and
TNF-a signaling appear to be distinct. Chelator treatment had no
e¡ect onTNF-a-mediated NF-kB activation or nuclear transloca-
tion. Previous studies have suggested that iron may be essential
for chromatin remodeling events required for TNF-a-mediated
activation of the VCAM-1 gene as well as other NF-kB-depen-
dent genes (Koo et al, 2003). IRF-1 induction by TNF-a may
require similar iron sensitive chromatin remodeling events.
Further de¢nition of the role of iron in these signaling pathways
may provide essential insights into the in£ammatory mediators in
the skin, the contributions of iron, and the potential value of iron
chelators for the treatment of in£ammatory skin disorders.
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